Elan posts $2.28bn income for Q2, focused on sale

Dublin-headquartered biotechnology company Elan has posted an income of $2.28bn (€1.7bn) for the second quarter of 2013, compared to a net loss of $28.5m for Q2 in 2012.

The company said income was impacted by $2.54bn due to restructuring of is collaboration with partner Biogen on the drug Tysabri, and a subsequent $1bn share buyback.